Evaluation of patients on sertindole treatment after failure of other antipsychotics: A retrospective analysis

Azorin, Jean-Michel; Murteira, Susana; Hansen, Karina; Toumi, Mondher
January 2008
BMC Psychiatry;2008, Vol. 8, Special section p1
Academic Journal
Background: Use of the atypical antipsychotic sertindole was suspended for four years due to safety concerns. During the suspension, the regulatory authorities required further studies, including this one, to be conducted. The purpose of this study was to determine if a subset of patients with psychotic illness exists which particularly benefits from sertindole treatment after failure of other antipsychotic drugs, including atypical antipsychotics. Methods: This was a retrospective single-arm observational crossover study of 344 patients, who served as their own controls. Patients mainly from the Sertindole Safety Study who had shown good response to sertindole, and who had followed up to four alternating six month periods of treatment with sertindole and other antipsychotics, were included. (In Period 1 patients took non-sertindole treatment, in Period 2, sertindole was taken, in Period 3, patients reverted to non-sertindole treatment, and in Period 4, sertindole was taken again.) Patient records for each period of treatment were assessed for objective data: number and duration of hospitalizations due to worsening of psychotic symptoms; the amount of self-harming behaviour; indicators of social status. Retrospective evaluation of changes in clinical symptoms from the patients' records was also conducted. Dates and reasons for stopping and/or switching medication were also recorded. Results: There was improvement in all objective measured parameters during the periods of sertindole treatment. In particular, the average number of hospitalizations per year due to worsening of psychotic symptoms was reduced in the following way in the group studied over four treatment periods: Period 1 (non-sertindole treatment) 3.4; Period 2 (sertindole treatment) 1.0; Period 3 (non-sertindole treatment) 2.0; Period 4 (sertindole treatment) 1.8. The duration of hospitalizations also decreased significantly during the periods of sertindole treatment. Results showed that patients improved in objective social parameters when switched to sertindole treatment; assessment of the patients' affective lives showed a significant increase in the number of patients having a stable relationship during sertindole treatment; and assessment of the number of patients employed showed an increase after the first and second switch to sertindole treatment (from Period 1 to Period 2 and from Period 3 to Period 4, respectively). Adverse events and lack of efficacy were the main reasons for switching to sertindole. Conclusion: A group of patients benefited from sertindole after other antipsychotic treatments, including that with atypical antipsychotics, had failed. Further studies are needed to investigate if there is a specific patient profile that corresponds to these responders.


Related Articles

  • Predictors of duration of admission following an act of deliberate self-harm, a cross section study from Oman. Al Salmi, Muna; Al-Difai, Zakiya; Al Sinawi, Hamed; al Fahdi, Amal // Middle East Journal of Psychiatry & Alzheimers;Nov2016, Vol. 7 Issue 2, p3 

    Objective: This study aims to determine the predictors of the length of inpatient hospital admission following deliberate self-harm (DSH). Method: This is a retrospective study; medical notes for all patients admitted from Jan 20012 to Jan 2014 with DSH were reviewed for sociodemographic...

  • Antipsychotics: Tuning muscarinic receptor signalling. Flight, Monica Hoyos // Nature Reviews Drug Discovery;Oct2008, Vol. 7 Issue 10, p806 

    The article discusses the study on the efficacy of LY2033298, a small molecule modulator that is specific for the muscarinic receptor subtype which shows effects in preclinical models of schizophrenia. It revealed that LY2033298 increased acetylcholine responses specifically at the muscarinic...

  • Antipsychotic use and diagnosis of delirium in the intensive care unit. Swan, Joshua T.; Fitousis, Kalliopi; Hall, Jeffrey B.; Todd, S. Rob; Turner, Krista L. // Critical Care;2012, Vol. 16 Issue 3, p1 

    Introduction: Delirium is an independent risk factor for prolonged hospital length of stay (LOS) and increased mortality. Several antipsychotics have been studied for the treatment of intensive care unit (ICU) delirium that has led to a high variability in prescribing patterns for these...

  • Antipsychotic compliance valuable in schizophrenia.  // PharmacoEconomics & Outcomes News;11/17/2007, Issue 541, p6 

    The article focuses on the results of a study which revealed that increases in compliance may lead to considerable cost-savings and health improvements presented at the 10th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Atypical...

  • Does Viloxazine Really Improve Sex Drive? A Double-Blind Controlled Study.  // British Journal of Psychiatry;May86, Vol. 148, p597 

    The action of viloxazine on libido and sex drive was evaluated with a randomised controlled double-blind trial against placebo on a population of 26 male out-patients affected by primary depression (DSM Ill). Modifications in the sexual sphere were assessed by the ad hoc inclusion of a series of...

  • Haloperidol: A Controlled Clinical Trial in Chronic Disturbed Psychotic Patients. Okasha, A.; Tewfik, G. I. // British Journal of Psychiatry;Jan64, Vol. 110 Issue 464, p56 

    The article discusses the results of the double-blind controlled trial of haloperidol and placebo in chronic disturbed psychotic patients. It was found that the haloperidol is slightly superior to placebo. Some condition and behavior of patients were improved by haloperidol. However, this...

  • Israeli firm to hold trial for schizophrenia.  // BioSpectrum;Jan2012, Vol. 10 Issue 1, p72 

    The article reports on the approval of regulatory authorities to commence the clinical trial of BL-1020, an anti-psychotic for the treatment of schizophrenia, developed by BiolineRX Ltd. in India.

  • Impact of Moxifloxacin versus Clarithromycin on Normal Oropharyngeal Microflora. Beyer, G.; Hiemer-Bau, M.; Ziege, S.; Edlund, C.; Lode, H.; Nord, C. E. // European Journal of Clinical Microbiology & Infectious Diseases;Jul2000, Vol. 19 Issue 7, p548 

    A multiple-dose, randomized, double-blind, controlled, cross-over trial was performed in 12 healthy male subjects in order to investigate the effect of a 7-day treatment with moxifloxacin (400 mg orally, once daily) versus clarithromycin (500 mg orally, twice daily) on the normal oropharyngeal...

  • Attitude and Drug Acceptance. Richards, Arnold D. // British Journal of Psychiatry;Jan64, Vol. 110 Issue 464, p46 

    The article examines the attitude of tranquilizer refusers and tranquilizer accepters on the basis of nurses and physicians' judgment and urine tests for phenothiazines. Refusers do not differ significantly from accepters in terms of age, length of stay in hospital or dose of drug. Urine tests...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics